Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease

NCT00004941 is registered in ClinicalTrials.gov with FDA Office of Orphan Products Development as lead sponsor.

NCT NCT00004941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00004941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease
Lead sponsor
FDA Office of Orphan Products Development
Phase
Phase 3
Overall status
Completed
Start date
July 31, 1996
Completion date
July 31, 1996
Enrollment
94
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease